Skip to main content
David A Reardon on Muck Rack

David A Reardon

As seen in: Color Research & Application, Nature, JAMA Oncology, Science Magazine, Cell Press, The Lancet, LifeNews.com, BioSpace, Future Medicine, ONCOLOGY journal and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David A

Contact David A, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma

|
By Jack Ghannam, Julian Bryan, Jakob Weiss, Daniel Kovarsky, David Merrell, Conor Messer, Kristy Schlueter-Kuck, Geoffrey G Fell, Mary Jane Lim-Fat, Gilbert Youssef, Rifaquat Rahman, Lei Qin, J. Thomas Janes III, McKayla Van Orden, Kathleen L. Pfaff, Andrew Gans Verified, Emma Lin, Raymond Y. Huang, Brian P. Danysh, Laxmi Parida, Shuqiang Li, Patrick Y Wen, E. Antonio Chiocca, Donna S. Neuberg, Keith L. Ligon, Itay Tirosh, David A Reardon, Gad Getz, Catherine J. Wu
| Nature Verified
Correction to: Nature Cancer https://doi.org/10.1038/s43018-026-01179-2, published online 3 June 2026. In the version of the article initially published, in the Abstract, “we profiled 181 ICB-treated GBM samples with bulk DNA sequencing” should have read “we profiled 181 ICB-treated GBM cases using bulk DNA sequencing”.
Open in Who Shared Issue with article?

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma

|
By Jack Ghannam, Julian Bryan, Jakob Weiss, Daniel Kovarsky, David Merrell, Conor Messer, Kristy Schlueter-Kuck, Geoffrey G Fell, Mary Jane Lim-Fat, Gilbert Youssef, Rifaquat Rahman, Lei Qin, Kathleen L. Pfaff, Andrew Gans Verified, Emma Lin, Raymond Y. Huang, Brian P. Danysh, Laxmi Parida, Shuqiang Li, Patrick Y Wen, E. Antonio Chiocca, Donna S. Neuberg, Keith L. Ligon, Itay Tirosh, David A Reardon, Gad Getz, Catherine J. Wu, J. Thomas Janes III, McKayla Van Orden
| Nature Verified
Abstract The determinants of immune checkpoint blockade (ICB) response in glioblastoma (GBM) with wild-type isocitrate dehydrogenase remain poorly understood. Here we profiled 181 ICB-treated GBM samples with bulk DNA sequencing, bulk RNA sequencing and single-nucleus RNA sequencing to investigate the genomic features associated with ICB outcomes.
Open in Who Shared Issue with article?

Clinical validation of a high-performance somatic exome sequencing assay: from target-enrichment strategy to variant calling

|
By Junko Tsuji, Micah Rickles-Young, Justin Abreu, Alyssa Friedman, Caroline Petersen, J. Bryan, Konrad Scheffler, Edyta Malolepsza, Mark Fleharty, Katie Larkin, Kenneth J. Livak, Shuqiang Li, David A Reardon, Catherine J. Wu, Patrick A. Ott, Heidi Rehm, Max Jan, Chip Stewart, Gad Getz, Varun Jain, Severine Catreux, Carrie L. Cibulskis, Niall J Lennon, Taylor O’Connell, Theo Heyns, Fanny Dao
| Nature Verified
Abstract Clinical whole-exome sequencing (WES) has revolutionized clinical diagnostics by enabling scalable, cost-effective molecular profiling to detect somatic variants and identify novel therapeutic targets. In particular, the clinical evaluation of somatic variants relies on both high-quality sequencing data and robust variant detection with rapid turnaround times.
Open in Who Shared Issue with article?
See all 47 licensed articles (57 Total)